Gilead Sciences Inc. (GILD)

64.60
NASDAQ : Health Technology
Prev Close 65.49
Day Low/High 64.38 / 65.25
52 Wk Low/High 60.32 / 79.61
Avg Volume 7.76M
Exchange NASDAQ
Shares Outstanding 1.27B
Market Cap 83.50B
EPS 4.20
P/E Ratio 15.71
Div & Yield 2.52 (3.51%)

Latest News

Gilead Presents New Data On Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) And TAF-Based Regimens For The Treatment Of HIV-1 In Children, Older Adults And Women

Gilead Presents New Data On Biktarvy® (Bictegravir, Emtricitabine And Tenofovir Alafenamide) And TAF-Based Regimens For The Treatment Of HIV-1 In Children, Older Adults And Women

Gilead Sciences, Inc. (NASDAQ: GILD) today announced 48-week results from a Phase 2/3 study (Study GS-US-380-1474) evaluating the efficacy and safety of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, BIC/FTC/TAF),...

Gilead Announces Data Demonstrating Non-Inferiority Of Once-Daily Descovy® Vs. Once-Daily Truvada® For Prevention Of HIV Infection

Gilead Announces Data Demonstrating Non-Inferiority Of Once-Daily Descovy® Vs. Once-Daily Truvada® For Prevention Of HIV Infection

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results from the DISCOVER trial, a two-year Phase 3 randomized, controlled, double-blind study evaluating the safety and efficacy of the investigational use of once-daily Descovy ® (emtricitabine 200 mg...

Gilead Announces Senior Management Change

Gilead Announces Senior Management Change

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Alessandro Riva, MD, Executive Vice President, Oncology Therapeutics, has decided to leave the company to pursue another opportunity.

Gilead Sciences To Present At The Barclays Global Healthcare Conference On Tuesday, March 12

Gilead Sciences To Present At The Barclays Global Healthcare Conference On Tuesday, March 12

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Robin L.

Gilead Sciences Launches Age Positively Initiative To Address Unique Challenges Of Aging Population Living With HIV

Gilead Sciences Launches Age Positively Initiative To Address Unique Challenges Of Aging Population Living With HIV

Gilead Sciences, Inc. (NASDAQ: GILD) today announced it is providing $17.

The Real Money Post Industrial Average Continues to Soar

The Real Money Post Industrial Average Continues to Soar

The RMPIA rose 10.5% during the first half of the current quarter.

Gilead Receives Approval In Canada For YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy For Adults With Relapsed Or Refractory Large B-cell Lymphoma After Two Or More Lines Of Systemic Therapy

Gilead Receives Approval In Canada For YESCARTA™ (Axicabtagene Ciloleucel) CAR T Therapy For Adults With Relapsed Or Refractory Large B-cell Lymphoma After Two Or More Lines Of Systemic Therapy

YESCARTA is a chimeric antigen receptor T (CAR T) cell therapy that is custom-made for each patient from his or her own T cells.

I Like These 2 Smaller Name Biotech Stocks

I Like These 2 Smaller Name Biotech Stocks

I still believe it will be a big year for buyouts across the biotech industry.

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences Falls on Failed Cirrhosis Drug Trial of Selonsertib

Gilead Sciences says Selonsertib, a new drug for treating NASH, a type of liver disease, failed Phase 3 trials.

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study Of Selonsertib In Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Announces Topline Data From Phase 3 STELLAR-4 Study Of Selonsertib In Compensated Cirrhosis (F4) Due To Nonalcoholic Steatohepatitis (NASH)

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that STELLAR-4, a Phase 3, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of selonsertib, an investigational, once-daily, oral inhibitor of apoptosis...

An Interesting Week For Dividends

An Interesting Week For Dividends

It's behavioral finance at its finest, and makes for a fascinating debate.

Gilead Sciences Drops Following Earnings Miss

Gilead Sciences Drops Following Earnings Miss

The biotech company reports downside bottom-line results, though it beats on revenue.

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Gilead Shares Fall After Hours as Company Misses on Quarterly Earnings

Medicine is a slow business and I view Gilead Sciences as a hold for now.

Gilead Sciences Announces 11 Percent Increase In First Quarter 2019 Dividend

Gilead Sciences Announces 11 Percent Increase In First Quarter 2019 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared an increase of 11% in the company's quarterly cash dividend, beginning in the first quarter of 2019.

Gilead Sciences Announces Fourth Quarter And Full Year 2018 Financial Results

Gilead Sciences Announces Fourth Quarter And Full Year 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2018.

Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell

Beyond Alphabet: 3 Other Notable Companies Reporting Results After the Bell

Seagate, Hartford Financial and Gilead are set to report after the bell Monday.

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

What the Super Bowl Can Teach Us About Our Portfolio: Market Recon

And why maintaining a small position in defense stocks is important.

Google, Trump, General Motors, New England Patriots - 5 Things You Must Know

Google, Trump, General Motors, New England Patriots - 5 Things You Must Know

U.S. stock futures rise modestly as investors focus on stronger-than-expected jobs and manufacturing data from the United States last week; Google parent Alphabet reports earnings Monday after the closing bell; Donald Trump says there's a 'good chance' of a trade deal with China; the New England Patriots win their sixth Super Bowl title.

Agenus Closes $150 Million Immuno-Oncology Transaction With Gilead

Agenus Closes $150 Million Immuno-Oncology Transaction With Gilead

LEXINGTON, Mass., Jan.

Gilead Sciences To Release Fourth Quarter And Full Year 2018 Financial Results On Monday, February 4, 2019

Gilead Sciences To Release Fourth Quarter And Full Year 2018 Financial Results On Monday, February 4, 2019

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2018 financial results will be released on Monday, February 4, after the market closes.

Japan's Ministry Of Health, Labour And Welfare Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir)

Japan's Ministry Of Health, Labour And Welfare Approves Gilead's Epclusa® (Sofosbuvir/Velpatasvir)

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg), a once-daily treatment for adults with chronic hepatitis C virus (HCV) infection...

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun

And it is happening not a moment too soon.

Celgene Deal Gets the M&A Ball Rolling in the New Year

Celgene Deal Gets the M&A Ball Rolling in the New Year

It seemed just a matter of time before M&A returned to the biotech industry with a vengeance.

Gilead Sciences To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7

Gilead Sciences To Present At The 37th Annual J.P. Morgan Healthcare Conference On Monday, January 7

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that members of the executive management team will participate in a fireside chat at the 37 th Annual J.

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

-- Agenus Webcast and Conference Call Scheduled for Today at 8:30a.m.ET --

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead And Agenus Enter Into Collaboration To Develop Immuno-Oncology Therapies

Gilead Sciences, Inc. (NASDAQ: GILD) and Agenus Inc.

Gilead Sciences And Scholar Rock Announce Strategic Collaboration To Develop Novel Therapies For Fibrotic Diseases

Gilead Sciences And Scholar Rock Announce Strategic Collaboration To Develop Novel Therapies For Fibrotic Diseases

Gilead Sciences, Inc. (NASDAQ: GILD) and Scholar Rock Holding Corporation (NASDAQ: SRRK) announced today that the companies have entered into a strategic collaboration to discover and develop highly specific inhibitors of transforming growth factor beta...

TheStreet Quant Rating: C (Hold)